阿扎胞苷在老年AML患者治疗中的可行性及对其T淋巴细胞亚群、1年期生存率的影响

Feasibility of Azactidine in the Treatment of Elderly Patients with AML and Its Effect on T Lymphocyte Subsets and 1-year Survival Rate

目的探讨阿扎胞苷在老年AML患者治疗中的可行性。方法本次研究在98例样本中进行,均自河南省人民医院中选取,此次研究对象为老年AML患者,于2018年3月至2021年12月完成选例,以随机数字表法为分组原则将患者分配成两组,其中一组49例接受CAG方案治疗,命名为对照组;另一组49例在对照组基础上联合阿扎胞苷治疗,命名为观察组。治疗时间:28 d,随访1年。比较两组各项指标。结果治疗后,观察组、对照组临床疗总有效率进行比较,前者更高;观察组、对照组治疗前、治疗后CD3+、CD4+、CD206+进行比较,均降低,组间比较,前者更低;观察组、对照组治疗后KPS评分进行比较,均升高,组间比较,前者更高;观察组、对照组术后1年生存率进行比较,前者更高(P<0.05)。结论阿扎胞苷治疗老年AML效果显著,调节免疫指标水平,改善生存质量。

Objective To investigate the feasibility of azactidine in the treatment of elderly patients with AML.Methods A total of 98 subjects were included in this study,all of which were selected from Henan Provincial People's Hospital.The subjects in this study were elderly AML patients,who were selected from March 2018 to December 2021.The patients were divided into two groups based on the random number table method.In one group,49 patients received CAG treatment and were named as the control group.The other group of 49 patients were treated with azactidine on the basis of control group and named as the observation group.Treatment time:28 d,follow-up time:1 year.The indicators of the two groups were compared.Results After treatment,the total effective rate of the observation group was higher than that of the control group.Compared with before treatment,CD3+,CD4+and CD206+all decreased of the observation group and the control group after treatment,and the former was lower.The KPS score of the observation group and control group increased after treatment,and the former was higher.The 1-year survival rate of the observation group was higher than that of the control group(P<0.05).Conclusion Azactidine therapy can effectively improve the clinical efficacy of elderly AML patients,regulate the level of immune indexes,improve the quality of life.